Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
复制标题
曲美曲沙治疗复发性儿童急性淋巴细胞白血病的 II 期试验：一项小儿肿瘤小组研究。
DOI：
10.1093/jnci/82.20.1641
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
Vietti,T
中科院分区：
文献类型：
--
作者：
Pappo,A;Dubowy,R;Ravindranath,Y;Alvarado,C;Rao,S;Whitehead,VM;Vega,R;Kamen,B;Vietti,T
包括完整的病史和体格检查，完整的血细胞计数，血清化学，凝血谱，胸片，心电图和骨髓抽吸物的组织学检查。通过连续血细胞计数、骨髓检查和重复的体格检查来监测治疗反应。将患者从研究中剔除的标准包括：3周后病情进展，6周后无反应，完全或部分有效后复发或进展性疾病，以及出现不可接受的毒性反应。
included a complete history and physical examination, complete blood count, serum chemistries, coagulation profile, chest radiograph, electrocardiogram, and histologic examination of bone marrow aspirate. Response to therapy was monitored by serial blood counts, bone marrow examinations, and repeated physical examinations. Criteria for removing patients from the study included progressive disease after 3 weeks, no response after 6 weeks, recurrent or progressive disease after complete or partial response, and development of unacceptable toxic effects.